John Young - Pfizer Group President of Global Established Pharma Bus.
| PFE Stock | MXN 448.17 3.06 0.69% |
President
Mr. John D. Young is the Group President Pfizer Innovative Health and Angela Hwang of Pfizer Inc, effective January 1, 2018. He was Group President, Global Established Pharma Business from January 2014 until June 2016. President and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Units Regional President for Europe and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until 2009. Director of Johnson Controls International plc. since 2018.
| Age | 58 |
| Tenure | 6 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
John Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Young against Pfizer stock is an integral part of due diligence when investing in Pfizer. John Young insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Young over two months ago Ambarella exotic insider transaction detected | ||
John Young over six months ago Acquisition by John Young of 1017 shares of Exelon subject to Rule 16b-3 | ||
John Young over six months ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3 | ||
John Young over six months ago Acquisition by John Young of 1029 shares of Exelon subject to Rule 16b-3 |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1332 % which means that it generated a profit of $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3687 %, meaning that it generated $0.3687 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Richard Hirst | Delta Air Lines | 69 | |
| Douglas Schutt | Costco Wholesale | 55 | |
| Brett Hart | United Airlines Holdings | 53 | |
| Russ Miller | Costco Wholesale | 60 | |
| William Payne | Air Transport Services | 53 | |
| Joanne Smith | Delta Air Lines | 60 | |
| Kate Gebo | United Airlines Holdings | 49 | |
| Irene Foxhall | United Airlines Holdings | 62 | |
| Linda Jojo | United Airlines Holdings | 58 | |
| Gregory Hart | United Airlines Holdings | 52 | |
| Michael Bonds | United Airlines Holdings | 53 | |
| John McKay | Costco Wholesale | 59 | |
| Andrew Nocella | United Airlines Holdings | 53 | |
| Paul Jacobson | Delta Air Lines | 47 | |
| Franz Lazarus | Costco Wholesale | 71 | |
| Andrew Levy | United Airlines Holdings | 46 | |
| Dennis Zook | Costco Wholesale | 67 | |
| Chris Kenny | United Airlines Holdings | 53 | |
| Rahul Samant | Delta Air Lines | 56 | |
| Ron Vachris | Costco Wholesale | 58 | |
| Wayne West | Delta Air Lines | 58 | |
Management Performance
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President of Global Established Pharma Bus. | ||
| Jennifer Damico, Controller VP | ||
| Frank DAmelio, CFO and Executive VP of Bus. Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Director | ||
| James Smith, Director | ||
| Christopher CFA, VP Officer | ||
| Dennis Ausiello, Independent Director | ||
| Mikael Dolsten, President - Worldwide Research and Development | ||
| Frances Fergusson, Independent Director | ||
| Stephen Sanger, Independent Director | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| DVM DVM, Chairman CEO | ||
| Geno Germano, Group President of Global Innovative Pharma Bus. | ||
| Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
| Sally Susman, Executive Vice President - Corporate Affairs | ||
| Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Freda LewisHall, Executive Vice President Chief Medical Officer | ||
| Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
| Mikael MD, Dev Research | ||
| Dan Littman, Director | ||
| Ian Read, Chairman, CEO and Chairman of Executive Committee | ||
| James Kilts, Independent Director | ||
| Don Cornwell, Independent Director | ||
| Charles Hill, Executive Vice President - Worldwide Human Resources | ||
| Joseph Echevarria, Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Scott Gottlieb, Director | ||
| Ronald Blaylock, Independent Director | ||
| Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
| Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 5.97 T | |||
| Shares Outstanding | 5.61 B | |||
| Shares Owned By Institutions | 70.47 % | |||
| Price To Earning | 27.15 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 59.69 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |